Truncated Norrin Protein for Retinal Vascular Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for capillary stabilization and vascular regeneration in retinal tissue are hindered by the short half-life of naturally occurring norrin proteins, which limits their effectiveness in addressing aberrations in retinal vascular development associated with conditions like Norrie disease, familial exudative vitreoretinopathy, and retinopathy of prematurity.
Innovation Solution
A method involving the use of a truncated norrin protein with a longer half-life, administered through intravitreal injection, to stimulate capillary stabilization and vascular regeneration by activating Wnt-signaling pathways, particularly through the Fzd4 receptor on endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naturally occurring norrin protein is used for capillary stabilization and vascular regeneration, then the therapeutic effect is achieved through Wnt-signaling activation, but the short half-life limits its effectiveness and requires frequent administration
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of norrin protein to create stable variants with altered half-life characteristics. Specifically, the invention introduces mutations that prevent proteolytic degradation while maintaining biological activity, thereby extending the duration of action from hours to days. This allows for less frequent intravitreal injections and sustained therapeutic effect in treating retinal vascular diseases.
Solution Approach 2:
The patent creates a stable variant that replaces the short-lived natural norrin protein. By engineering norrin with enhanced stability, the invention eliminates the need for frequent re-administration, effectively replacing a short-living therapeutic agent with a long-acting version that maintains therapeutic levels in the vitreous humor for extended periods.
2Reliability
If frequent intravitreal injections are administered to maintain therapeutic levels of norrin, then capillary stabilization is achieved, but the treatment complexity and patient burden increase
Solution Approach 1:
The patent modifies the stability parameter of norrin protein through amino acid mutations, transforming it from a short-half-life molecule requiring frequent injection to a long-half-life molecule suitable for monthly or less frequent administration. This parameter change directly reduces treatment complexity and patient burden while maintaining capillary stabilization efficacy.
3Reliability
If full-length norrin protein is used, then complete biological activity is achieved, but the protein size and potential for degradation increase
Solution Approach 1:
The patent extracts and removes specific amino acid sequences from the full-length norrin protein that are responsible for rapid degradation. By deleting or mutating these vulnerable regions while retaining the core functional domains (particularly the cysteine-knot motif essential for Fzd4 binding), the invention creates a truncated but stable protein variant with extended half-life and maintained biological activity.
Solution Approach 2:
The invention changes the structural parameters of norrin by introducing point mutations and truncations that enhance proteolytic resistance. These modifications alter the protein's susceptibility to degradation without compromising its ability to activate Wnt-signaling pathways, thereby improving stability while preserving biological function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The truncated norrin protein effectively promotes vascular recovery and reduces avascular areas and neovascular tufts in oxygen-induced retinopathy models, demonstrating its potential in treating retinal vascular diseases by enhancing vascular growth and stability.
Implementation Method 1
to stimulate capillary stabilization and vascular regeneration by activating Wnt-signaling pathways, particularly through the Fzd4 receptor on endothelial cells
Data Source
AI summary
A synthetic truncated norrin protein is provided. The synthetic truncated norrin protein is a −24 residue N-terminus norrin truncate relative to SEQ ID. NO. 1 that retains the cysteine-knot motif and frizzled-4 binding properties and has a mutation in the cysteine-knot motif in at least one position 81-90 of SEQ ID. NO. 1 that interferes with protease cleavage of the resulting protein thereby extending the biological half-life thereof in vivo relative to native norrin.